Humanized mouse model of ovarian cancer recapitulates patient solid tumor progression, ascites formation, and metastasis

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Bankert, Richard B ^a   Balu Iyer, Sathy V ^b   Odunsi, Kunle ^c   Shultz, Leonard D ^d   Kelleher Jr , Raymond J ^a   Barnas, Jennifer L ^a   Simpson Abelson, Michelle ^a,e   Parsons, Robert ^a   Yokota, Sandra J ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

^d JACKSON LABORATORY   (United States)

^e UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CD20 ANTIGEN; CD45 ANTIGEN; CHOLESTEROL; CYTOKERATIN; DIMYRISTOYLPHOSPHATIDYLGLYCEROL; DISTEAROYLPHOSPHATIDYLCHOLINE; GAMMA INTERFERON; HLA ANTIGEN CLASS 2; IMMUNOGLOBULIN; LIPOSOME; NY ESO 1 ANTIGEN; RECOMBINANT INTERLEUKIN 12; SYNDECAN 1; INTERLEUKIN 12;

ABDOMINAL DISTENSION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASCITES; ASCITES FLUID; B LYMPHOCYTE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL AGGREGATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLAST; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LIVER; LUNG METASTASIS; LYMPHOCYTE; METASTASIS POTENTIAL; MOUSE; NONHUMAN; OMENTUM; OVARY ADENOCARCINOMA; OVARY CANCER; OVARY CARCINOMA; PANCREAS; PAPILLARY CARCINOMA; PERITONEAL CAVITY; PLASMA CELL; REGULATORY T LYMPHOCYTE; SOLID TUMOR; SPLEEN; STOMACH; STROMA; TH17 CELL; TUMOR GROWTH; TUMOR LOCALIZATION; TUMOR MICROENVIRONMENT; ANIMAL; BLOOD; DISEASE COURSE; DISEASE MODEL; HUMAN; IMMUNOASSAY; METABOLISM; METASTASIS; OVARY TUMOR; PATHOLOGY;

MUS;

ANIMALS; ASCITES; CA-125 ANTIGEN; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; INTERFERON-GAMMA; INTERLEUKIN-12; MICE; NEOPLASM METASTASIS; OVARIAN NEOPLASMS;

EID: 80052838187     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0024420     Document Type: Article

References (46)

1. Reddy S, Piccione D, Takita H, Bankert RB, (1987) Human lung tumor growth established in the lung and subcutaneous tissue of mice with severe combined immunodeficiency. Cancer Res 47: 2456-2460.
2. Shultz LD, Ishikawa F, Greiner DL, (2007) Humanized mice in translational biomedical research. Nature Rev Immunol 7: 118-130.
3. Bankert RB, Egilmez NK, Hess SD, (2001) Human-SCID mouse chimeric models for the evaluation of anti-cancer therapies. TRENDS in Immunol 22: 386-393.
4. Erez N, Truitt M, Olson P, Hanahan D, (2010) Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner. Cancer Cell 17: 135-147.
5. Simpson-Abelson MR, Sonnenberg GF, Takita H, Yokota SJ, Conway TJ Jr, et al. (2008) Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rγnull mice. J Immunol 180: 7009-7018.
6. Armstrong DK, Bundy B, Winzel L, Huang HQ, Baergen R, et al. (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354: 34-43.
7. Vergote I, et al. (2010) Neoadjuvant chemotherapy or primary surgery in Stage IIIC or IV ovarian cancer. N Engl J Med 363: 943-953.
8. Gupta D, Lis CG, (2009) Role of CA125 in predicting ovarian cancer survival - a review of the epidemiological literature. J Ovar Res 2: 13 doi:10.1186/1757-2215-2-13.
9. Bast RC Jr, Klug TL, St. John E, Jenison E, Niloff JM, et al. (1983) A radioimmunoassay using a monoclonal antibody to monitor the course of epithealial ovarian cancer. N Engl J Med 309: 883-887.
10. Barnas JL, Simpson-Abelson MR, Brooks SP, Kelleher RJ, Bankert RB, (2010) T cells and Stromal Fibroblasts in Human Tumor Microenvironments Represent Potential Therapeutic Targets. Cancer Microenvironment 3: 29-47.
11. Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, Beck A, Miller A, et al. (2010) Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A 107: 7875-7880.
12. Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H, et al. (2001) Regulatory CD4+CD25+ T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 61: 4766-4772.
13. Sato E, et al. (2005) Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 102: 18538-18543.
14. Kryczek I, Wei S, Zhu G, Myers L, Mottram P, et al. (2007) Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer Res 67: 8900-8905.
15. Miyahara Y, Odunsi K, Chen W, Peng G, Matsuzaki J, et al. (2008) Generation and regulation of human CD4+ IL-17-producing T cells in ovarian cancer. Proc Natl Acad Sci U S A 105: 15505-15510.
16. Zou W, (2005) Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nature Rev Cancer 5: 263-274.
17. Broderick L, Brooks SP, Takita H, Baer AN, Bernstein JM, et al. (2006) IL-12 reverses anergy to T cell receptor triggering in human lung tumor-associated memory T cells. Clin Immunol 118: 159-169.
18. Simpson-Abelson M, Bankert RB, (2008) Targeting the TCR signaling checkpoint: a therapeutic strategy to reactivate memory T cells in the tumor microenvironment. Expert Opin Ther Targets 12: 477-490.
19. Simpson-Abelson M, Purohit VS, Pang WM, Iyer V, Odunsi K, et al. (2009) IL-12 Delivered Intratumorally by Multilamellar Liposomes Reactivates Memory T Cells in Human Tumor Microenvironments. J Clin Immunol 132: 71-82.
20. Singh S, Ross SR, Acena M, Rowley DA, Schreiber H, (1992) Stroma is critical for preventing or permitting immunological desctruction of antigenic cancer cells. J Exp Med 175: 139-146.
21. Ochsenbei AF, Klenerman P, Karrer U, Ludewig B, Pericin M, et al. (1999) Immune surveillance against a solid tumor fails because of immunological ignorance. Proc Natl Acad Sci USA 96: 2233-2238.
22. Zhang B, Bowerman NA, Salama JK, Schmidt H, Spiotto MT, et al. (2007) Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J Exp Med 204: 49-55.
23. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, et al. (2005) Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121: 335-348.
24. Nazareth MR, Broderick L, Simpson-Abelson MR, Kelleher RJ Jr, Yokota SJ, et al. (2007) Characterization of Human Lung Tumor-Associated Fibroblasts and Their Ability to Modulate the Activation of Tumor-Associated T Cells. J Immunol 178: 5552-5562.
25. Nauta AJ, Fibbe WE, (2007) Immunomodulatory properties of mesenchymal stromal cells. Blood 110: 3499-3506.
26. Bombara MP, Webb DL, Conrad P, Marlor CW, Sarr T, et al. (1993) Cell contact between T cells and synovial fibroblasts causes induction of adhesion molecules and cytokines. J Leukoc Biol 54: 399-406.
27. Barnas JL, Simpson-Abelson MR, Brooks SP, Kelleher RJ, Bankert RB, (2010) Reciprocal functional modulation of the activation of T lymphocytes and fibroblasts derived from human solid tumors. J Immunol 185: 2681-2692.
28. Allen M, Jones JL, (2011) Jekyll and Hyde: the role of the microenvironment on the progression of cancer. J Pathol 223: 162-176.
29. Whiteside TL, (2008) The tumor microenvironment and its role in promoting tumor growth. Oncogene 27: 5904-5912.
30. van Dalen A, et al. (2000) Prognostic significance of CA 125 and TPS levels after 3 chemotherapy courses in ovarian cancer patients. Gynecol Oncol 79: 444-450.
31. Levanon K, Crum C, Drapkin R, (2008) New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol 26: 5284-5293.
32. Martini Diniz P, Carvalho JP, Chada Baracat E, Carvalho FM, (2011) Fallopian tube origin of supposed ovarian high-grade serous carcinomas. Clinics 66: 73-76.
33. Ranvier L, (1874) Du development et de l'accroisement des vaisseux sanguins. Arch Physiol 1: 429-450.
34. Gerber SA, Rybalko VY, Bigelow CE, Lugade AA, Foster TH, et al. (2006) Preferential attachment of peritoneal tumor metastases to omental immune aggregates and possible role of a unique vascular microenvironment in metastatic survival and growth. Am J Pathol 169: 1739-1752.
35. Sorensen EW, Gerber SA, Sedlacek AL, Rybalko VY, Chan WM, et al. (2009) Omental immune aggregates and tumor metastasis within the peritoneal cavity. Immunol Res 45: 185-194.
36. Khan S, Taylor JL, Rinker-Schaeffer CW, (2010) Disrupting ovarian cancer metastatic colonization: Insights from metastasis suppressor studies. J Oncol pp. 7.
37. Benedet JL, Bender H, Jones H III, Ngan HY, Pecorelli S, (2000) FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. GICO Committee on Gynecologic Oncology. Intl J Gynaecol Obstet 70: 209-262.
38. Chen SS, Spiegel G, (1991) Stage I endometrial carcinoma: role of omental biopsy and omentectomy. J Reprod Med 36: 627-629.
39. Usubu{double acute}tu{double acute}n A, Ozseker HS, Himmetoglu C, Balci S, Ayhan A, (2007) Omentectomy for gynecologic cancer. How much sampling is adequate for microscopic examination? Arch Pathol Lab Med 131: 1578-1581.
40. Egilmez NK, Jong YS, Sabel MS, Jacob JS, Mathiowitz E, et al. (2000) In situ tumor vaccination with interleukin-12 encapsulated biodegradable microspheres: Induction of tumor regression and potent antitumor immunity. Cancer Res 60: 3832-3837.
41. Hill HC, Conway TF Jr, Sabel MS, Jong YS, Mathiowitz E, et al. (2002) Cancer immunotherapy with interleukin-12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: Coinduction of innate and adaptive antitumor immunity and cure of disseminated disease. Cancer Res 62: 7254-7263.
42. Nair RE, Jong YS, Jones SA, Sharma A, Mathiowitz E, et al. (2006) IL-12 + GM-CSF microsphere therapy induces eradication of advanced spontaneous tumors in Her-2/neu transgenic mice but fails to achieve long-term cure due to the inability to maintain effector T-cell activity. J Immunother 29: 10-20.
43. Wang Y, et al. (2005) An orthotopic metastatic prostate cancer model in SCID mice via grafting of a transplantable human prostate tumor line. Lab Invest 85: 1392-1404.
44. Yang S, Wen D, Hou J, He J, Chen J, (2008) Establishment of orthotopic transplantation model of human bladder cancer and detection by MRI. The Chinese-German J Clin Oncol 7: 51-54.
45. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, et al. (2008) Efficient tumour formation by single human melanoma cells. Nature 156: 593-598.
46. Liu H, et al. (2010) Cancer stem cells from human breast tumors are involved in spontaneous metastases in orthotopic mouse models. Proc Natl Acad Sci U S A 107: 18115-18120.